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Introduction
Tick-borne encephalitis (TBE) is a central nervous system infection caused by tick-borne encephalitis virus (TBEV) and transmitted to humans predominantly by tick bites. The incidence of TBE has increased during the past few decades and is a growing health problem in almost all European and Asian countries with endemic TBE. The clinical spectrum of the disease ranges from mild meningitis to severe meningoencephalitis with or without pareses [1] . It is well established that increasing age of patients is associated with a more severe course of acute illness and a less favourable outcome [2] and that TBE caused by the European virus subtype has a milder course and better outcome than TBE caused by Siberian or Far East subtypes [1] . In central Europe, the case fatality rate is 0.5-2%, about 5% of patients are affected by permanent pareses, and more than one-third suffer from postencephalitic syndrome [3] .
There is no specific antiviral treatment for TBE, but vaccination can effectively prevent the disease. Two such vaccines are licensed in Europe: FSME-IMMUN and Encepur (TicoVac in some countries); both are safe and highly effective, and after a complete basic course of vaccination, ≥98% of vaccinees are protected. However, regular booster doses are needed to maintain the high protection rate [4] .
Slovenia is a small central European country of about 20 000 square km, with a dense river network and more than half the territory covered by forest. The country has approximately two million inhabitants; the human settlement is dispersed and uneven. A large part of Slovenia is endemic for TBE, and notification of cases has been mandatory since 1977. The typical annual number of cases is 150-250, with pronounced variability from year to year. In the period 2000-2015, the incidence rates ranged from three to 15 per 100 000 inhabitants [5] . Despite the fact that Slovenia has one of the highest reported incidence rates of TBE in Europe, vaccine uptake remains low: according to results obtained in 2007, the proportion of persons aged ≥15 years ever vaccinated against TBE was only about 12% [6] .
The number of patients reported as developing vaccination breakthrough TBE is low [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , and information on this group is limited. The aim of this study was to determine the proportion of such patients and to compare the course and outcome in this group with findings in unvaccinated patients who developed TBE. We have analysed a large and detailed TBE data set compiled at our institution, where over two-thirds of patients diagnosed with TBE in Slovenia are hospitalized.
Patients and methods
The study was performed according to the Declaration of Helsinki and was approved by the Medical Ethics Committee of the Ministry of Health of the Republic of Slovenia (152/06/13).
Selection of patients
Patients >15 years old diagnosed with TBE at the Department of Infectious Diseases of the UMC Ljubljana in the period January 2000 to December 2015 and who had received at least two doses of TBE vaccine prior to the onset of their illness qualified for the present report. For each patient who developed breakthrough TBE, two unvaccinated sex-and age-matched patients diagnosed with TBE in the same year were included for comparison. If more than two patients fulfilled the criteria, those with the surname alphabetically nearest to the index patient were chosen as controls. Patients with a history of previous infections or vaccinations against other flaviviruses were excluded.
A detailed history was obtained for all patients, including information on vaccination against TBE. Patients were examined physically, and routine blood and CSF parameters were acquired (cell counts, concentration of total proteins, glucose, albumin, and IgG, IgA and IgM antibody levels) at the initial visit. During hospitalization, signs and symptoms of TBE were evaluated and recorded daily.
Patients with antecedent vaccination against TBE were followed up clinically at 14 days, 6-8 weeks, 6 months and 12 months after the first visit. Serum samples were collected at each visit. Control patients with an uneventful clinical course had a follow-up examination only at 6-8 weeks, but those who reported complaints were followed as for patients with breakthrough TBE.
Case definition
Diagnosis of TBE was considered confirmed by the presence of clinical signs/symptoms of meningitis/ meningoencephalitis, elevated CSF leucocyte count (>5 9 10 6 cells L
À1
), and the presence of serum IgM and IgG antibodies to TBEV. For patients with breakthrough TBE, intrathecal synthesis of specific IgM and/or IgG antibodies was also evaluated.
Assessment of the severity of TBE
Our hypothesis was that the clinical course in patients with breakthrough TBE was more severe than in sex-and age-matched unvaccinated patients. The premise was based on reports of relatively severe illness in several previously vaccinated patients [8-11, 13, 16] . We assessed disease severity using simple clinical classification and quantitative evaluation (primary outcomes), and by the presence of individual clinical findings indicative of severe disease (secondary outcomes).
Tick-borne encephalitis was assigned as mild (only signs or symptoms of meningeal involvement), moderate (monofocal neurological signs and/or mild-to-moderate signs/symptoms of central nervous system dysfunction) or severe (multifocal neurological signs and/or signs/symptoms of severe central nervous system dysfunction).
In addition to this simple clinical classification, disease severity was evaluated quantitatively using a standardized questionnaire as reported elsewhere [20] . In short, points (1-9) were assigned for the presence, intensity and duration of headache, fever, vomiting and meningeal signs; the presence of tremor, pareses, urine retention and cognitive function disturbances; the presence and intensity of conscious disturbances; and the need for and duration of treatment of elevated intracranial pressure. Absence of a particular symptom/ sign scored zero. Overall scores ≤8, 9-22 and >22 corresponded to clinically mild, moderate and severe disease, respectively [20] .
Complete and incomplete basic vaccination
Patients who had obtained at least three doses of TBE vaccine before illness onset were interpreted to receive complete basic vaccination, whilst those who had received only two doses of the vaccine were interpreted to receive incomplete basic vaccination.
Serological evaluation
At our institution, all patients with aseptic meningitis, meningoencephalitis or meningoencephalomyelitis are routinely tested for infection with Borrelia burgdorferi sensu lato and TBEV. The presence of serum and CSF IgM and IgG antibodies to TBEV is assessed using the Enzygnost â Anti-TBE Virus (IgM, IgG) test (SiemensGmbH, Marburg, Germany) in accordance with the manufacturer's instructions. Antibodies to B. burgdorferi sensu lato in serum and CSF are determined using an indirect chemiluminescence immunoassay (LIAISON â , Diasorin, Italy) with recombinant antigens OspC and VlsE for the detection of IgM antibody and VlsE for IgG. Results were graded according to the manufacturer's instructions.
Intrathecal TBE/borrelia IgM and/or IgG antibody production is calculated using Reiber 0 s formula: values >1.4 are interpreted as indicating intrathecal antibody production [21] .
TBE IgG antibody avidity
To differentiate between primary TBEV infection and breakthrough infection in vaccinated individuals, the avidity of specific IgG antibodies to TBEV was determined using the TBE Virus ELISA (IgG) test (EUROIMMUNE AG, Luebeck, Germany), following the manufacturer's instructions. For objective interpretation, the relative avidity index (RAI) is expressed as a percentage using the extinction values with and without urea treatment: the upper limit of the range of low-avidity antibodies is RAI 40%, values between RAI 40% and 60% are equivocal, and values above RAI 60% are considered as high-avidity antibodies.
Statistical analysis
Numerical variables are summarized as medians with range or, when specified, interquartile range (IQR), categorical variables as frequencies (percentages, with 95% confidence intervals [CIs] ). Association between the covariates and vaccination status was assessed using univariate conditional logistic regression analysis of matched sets comprising one case and two controls. Comparisons between patients with complete and incomplete basic vaccination were based on univariate logistic regression. Firth's correction was used for covariates showing complete or quasi-complete separation between groups. Results were expressed as odds ratios (ORs) with their 95% CIs and P values.
Association between the level of TBE IgM antibodies and vaccination status (unvaccinated, complete basic vaccination, incomplete basic vaccination) was assessed using linear regression, adjusting the analysis for time since onset of disease; the outcome was log-transformed. TBE IgG antibody levels and the IgG RAIs were analysed similarly. The analyses were repeated on the two subset of vaccinated patients with adjustment for time elapsed since vaccination. Results were expressed as estimated average outcome ratios, and their 95% CIs were derived using the delta method. R statistical language was used for the analysis [22] .
To control for false positives and take into account the possible correlation between covariates, the P values reported in each table were adjusted using a multivariate permutation procedure [23] .
Results
Amongst 2332 adult patients diagnosed with TBE in the period 2000-2015, 39 (1.7%, 95% CI: 1.2-2.3%) had been vaccinated against TBE (FSME-IMMUNâ Baxter, Austria). Their median age was 59 (20-83) years; 22 of 39 (56.4%) were male. Twenty-five of the 39 previously vaccinated patients (64.1%) had received at least three doses of vaccine (complete basic vaccination); the other 14 patients had received only two doses before illness onset (incomplete basic vaccination). Three of the 39 patients with breakthrough TBE have been reported previously; all three had received complete basic vaccination [12] .
The subgroup of 25 patients with complete basic vaccination comprised 11 women and 14 men with a median age of 61 (39-83) years; 16 of 25 had received solely three doses of TBE vaccine, the remaining nine had also had at least one booster dose. The median time interval between the last dose of TBE vaccine and illness onset was 36 (1-180) months. In nine of 25 (36%) patients, the time interval was longer than that recommended by the vaccine producer for receiving the subsequent vaccine dose (3 years for those who had only three doses of basic vaccination or had ≥1 booster dose and were older than 60 years; 5 years for persons <60 years old who had ≥1 booster dose).
The subgroup of 14 patients who had TBE following incomplete basic vaccination comprised six women and eight men, median age 43 (20-70) years. The median time interval between the last dose of TBE vaccine and illness onset was 4.5 (1-120) months. In four of the 14 (28.6%) patients, the time interval was >12 months, stated by the vaccine producer as the longest recommended interval between the second and the third doses of vaccine.
Comparison of clinical and epidemiological data in patients who received complete or incomplete basic vaccination (Table 1) found no substantial differences, with the exception that those with incomplete vaccination were younger than patients who had a complete course.
Search for Borrelia burgdorferi sensu lato infection
With the exception of one patient from the control group all patients with TBE were tested also for the presence of borrelial antibodies in serum and CSF. Serum IgG antibodies to B. burgdorferi sensu lato were present in nine of 39 patients (23.1%, 95% CI: 11.1-39.3%) with breakthrough TBE and in 14 of 77 (18.2%, 95% CI: 10.3-28.6%) patients with TBE who had not been vaccinated against TBE. However, none of the patients fulfilled criteria for Lyme neuroborreliosis [24] since in no one intrathecal borrelial antibody production was established.
Acute illness
In comparison with unvaccinated patients with TBE, those who developed vaccine breakthrough TBE more often experienced a monophasic course of illness, had higher CSF leucocyte counts, more often had urine retention, conscious disturbance and pareses, more often needed ICU treatment and were hospitalized for longer. Detailed information is given in Table 2 . Assessment of the severity of the acute illness found a higher proportion of patients with clinically severe illness and a higher point score in the vaccinated group than in the ageand sex-matched unvaccinated group (14 vs 11, P < 0.001) ( Table 2 ).
Outcome
None of the patients in the study died during their acute illness. In the majority, the course of illness during a 1-year follow-up was relatively smooth and the outcome favourable. Only three of 25 (12%; 95% CI: 2.6-31.2%) patients who had received complete basic vaccination, and 0 of 14 (0%; 95% CI: 0-23.2%) who had received only two doses of vaccine, had an unfavourable outcome manifested by objective findings 1 year after the acute illness; the corresponding proportions for pronounced subjective complaints attributable to TBE but without objective findings were three of 25 (12%; 95% CI: 2.6-31.2%) and one of 14 (7%; 95% CI: 0.2-33.9%), respectively. Table 3 shows the occurrence of signs/symptoms in breakthrough disease at presentation and 6-8 weeks later in comparison with findings in sexand age-matched unvaccinated control patients. Overall, the vaccinated patients presented more symptoms than unvaccinated patients in the acute phase of the illness and, to a lesser extent, also 6-8 weeks later (when differences were smaller and not statistically significant).
Antibodies to TBEV
Findings are shown in Fig. 1 . At the initial testing, specific serum IgM antibodies (levels above the cutoff) were more often present in unvaccinated patients with TBE than in patients with breakthrough disease: 76 of 78 (97.4%, 95% CI: 91.0-99.7%) versus 27 of 39 (69.2%, 95% CI: 52.4-82.0%); P < 0.001. The frequency of specific IgM antibodies in the two vaccinated subgroups with breakthrough TBE was similar: 16 of 25 (64%, 95% Association between various covariates and vaccination status was assessed using univariate conditional logistic regression models for the matched sets comprising one case and two controls. In two of 39 patients with breakthrough TBE, the findings were markedly diverse in comparison with the other 37 patients: both patients had specific serum IgM antibodies and both had specific IgG levels in the range seen in unvaccinated patients with TBE [25] . In the other 37 patients with breakthrough TBE, the IgG antibody level was ≥230 U ml À1 (Fig. 1) . One of the two patients, a 54-year-old man who had received basic vaccination (no subsequent booster doses) 15 years before the onset of a biphasic TBE, was admitted to hospital on day 5 of the meningoencephalitic phase of his illness. At that time, he had serum IgM antibodies to TBEV, low levels of specific IgG antibody (27.1 U ml À1 ), and a low IgG RAI (9.2%), suggesting that previous vaccination against TBE had been ineffective in evoking an antibody response; the patient showed intrathecal synthesis of specific IgG antibodies (index 99.5). The other patient, a 28-year-old man, had received a second dose of vaccine 10 months before the onset of a biphasic TBE. He was admitted on day 2 of the meningoencephalitic phase of his illness. This patient also had lower levels of serum IgG antibodies (55 U ml
À1
) with lower RAI (15.9%) than the other patients, but intrathecal production of specific IgM and IgG antibodies was confirmed (indexes 33.9 and 16.7, respectively).
In linear regression modelling, levels of TBE IgM and IgG antibodies and the IgG RAI at the initial visit were associated with antecedent vaccination but not with duration of illness (days from the beginning of the meningoencephalitic phase, Table 4 ), with the exception of IgG that appeared to increase with illness duration. Unvaccinated patients had higher average levels of TBE IgM and lower levels of IgG antibodies and IgG RAI. Overall, patients with incomplete and complete basic vaccination had similar TBE IgG levels and IgG avidity, whereas IgM levels in patients with incomplete basic vaccination were 1.6 times higher than in patients who had a complete basic vaccination, although the difference was not statistically significant. All three values slightly decreased with the time elapsed since the last dose of vaccine; the biggest decrease was for the IgG RAI (Table 4) .
Discussion
TBE vaccines licensed in Europe are reported to be safe and highly effective: 14 days after the second dose of basic vaccination about 85% of persons develop protective antibodies, and after three doses (complete basic vaccination), 98-99.5% of persons with normal immunity are protected. However, regular booster doses are needed to maintain the high protection rate [4, 26] . 2332 (70.6%) were diagnosed with TBE at our institution and 39 of these (1.7%) had received at least two doses of TBE vaccine. Amongst the 39 patients, 25 had received a complete basic vaccination course with or without additional booster dose(s); in nine of 25 (36%), the time interval from the last dose to the onset of TBE was longer than the interval proposed by the vaccine producer for receiving a booster dose [4] . According to an analysis for 2007, only about 12% of Slovenian persons aged ≥15 years have ever been vaccinated against TBE, and merely 5% of the population received a complete course of basic vaccination [6] . Although our study most probably included the large majority of Slovenian patients who developed breakthrough TBE, we cannot reliably assess the field efficacy of the vaccine as we did not have precise data on the proportion and age of vaccinated persons during the study time frame.
Of the 39 patients in the present study who developed breakthrough TBE, 22 (56.4%) were male, a sex ratio similar to that for all notified TBE cases in Slovenia (of 3304 patients ≥15 years old registered with TBE in Slovenia in 2000-2015, the proportion of males was 57.2%). However, vaccinated patients were older than 3304 patients registered with TBE in the same time period: median 59 (20-83) versus 44 (15-75+) years, respectively [5] , which corresponds well with other reports indicating higher age in previously vaccinated patients with breakthrough TBE [10] [11] [12] [13] [14] [15] [16] and implies less effective protection in older people, possibly due to decreased immunological responsiveness to vaccination and increased risk of vaccine failure [14, 16, [27] [28] [29] . The exact mechanisms remain unknown.
Information on patients developing breakthrough TBE is limited, probably because numbers of such patients are low. A PubMed literature review identified 13 reports on patients with TBE despite vaccination [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , encompassing a total of 126 patients (Table 5) . Information on the severity of the acute illness is provided for only some of the patients. The relatively severe illness in several previously vaccinated patients [8-11, 13, 16] was interpreted as the consequence of such patients being older than the average adult patient with TBE, higher age being a risk factor for a more severe course of the disease [2, 9, 30] .
Direct comparison of the severity of acute illness in patients with breakthrough TBE with age-and sex- Adjusted R 2 ; overall P value 0; P = 0.40 0.02; P = 0.28 0.12; P = 0.07
Numbers are estimated average ratios of the outcome variable (between the category and the reference for categorical covariates, for numerical covariates between patients that differ by one unit in the value of numerical covariates); 95% confidence intervals (CIs) were obtained using the delta method. P values are Wald P values obtained from the log-linear models. a Missing for 31 patients. matched unvaccinated control patients with TBE, as in the present study, has not been reported previously. Our study shows that TBE has a more severe course of acute illness in previously vaccinated than in unvaccinated persons, as indicated by quantitative evaluation of the severity of illness and simple clinical classification, as well as by the presence of individual clinical findings indicative of severe disease, including duration of hospitalization, proportion of patients needing ICU treatment, and proportion of patients having evident conscious disturbances, urine retention, and pareses of one or more extremities and/or trunk. As suggested previously [7, 8, 10, 28, 31] , it appears that vaccination that does not protect an individual may have an adverse effect on the outcome. In the present study, we did not find an obvious alternative explanation for the more severe illness in previously vaccinated patients. In comparison with unvaccinated patients with TBE, the patients with breakthrough disease did not have more frequent and/or more severe underlying chronic illnesses or a known immune impairment. However, another reason why patients with pre-existing but nonprotective antibodies appear to have a more severe course of disease could be that the diagnosis of TBE in some patients a priori is discounted because the patient had a history of TBE vaccination [11] and that the ratio of consequently neglected TBE cases is higher in patients with mild illness than in those with severe disease for whom a more comprehensive diagnostic workup in usually performed. The likelihood of such diagnostic bias in the present study is low, if not negligible, because all patients were diagnosed at a single institution with extensive TBE experience, and the strict diagnostic approach included TBE serological testing for all patients with aseptic meningitis; in addition, TBE vaccine breakthrough was actively searched for.
It is acknowledged that severe acute illness is a risk factor for unfavourable outcome [8, 30] . In our study, the outcome in previously vaccinated patients was relatively favourable: only 7/39 (17.9%; 95% CI: 7.5-33.5%) had an unfavourable outcome, manifested with objective findings (three patients) or pronounced subjective complaints attributable to TBE without objective findings (four patients) 1 year after the acute illness. However, for precise assessment of outcome, the number of patients in the study should have been much larger and an appropriate control group followed up in exactly the same way as for vaccinated patients.
In general, the serological findings of the present study accord with previous reports. It is well recognized that patients with TBE have detectable specific serum IgM antibodies to the virus and the vast majority also have IgG antibodies at the beginning of the meningoencephalitic phase, also that levels of IgM antibodies are relatively high, with levels of IgG antibodies usually in the lowpositive range [25] . In contrast, patients who develop breakthrough TBE generally have very high TBEV IgG antibody levels but absent or low IgM antibody in the first days of the meningoencephalitic phase [32] . We expected that all our 25 patients with breakthrough TBE despite having had a complete basic course of vaccination would show this particular antibody pattern, and that amongst the 14 patients who received only two vaccine doses before the onset of TBE, the majority would react serologically as vaccinated persons and a minority as unvaccinated persons. Accordingly, all but two of 39 patients with breakthrough TBE (one with incomplete basic vaccination and one who had all three basic vaccine doses) showed a typical serology pattern for vaccinated persons. The absence of the expected antibody pattern was not a surprise for a patient who had received only two doses of vaccine (14 days after the second dose about 85% of vaccines develop protective antibodies, 15% do not) [4] , but was somewhat unexpected for the patient who had received three doses of basic vaccination (although the last dose was 15 years before the onset of TBE) and who reacted serologically as an immunologically na€ ıve person. Nevertheless, our results further corroborate previous reports [7, 9, [27] [28] [29] that primary vaccine failure (complete nonresponsiveness to vaccination) is rare and that the large majority of TBE vaccination failures are secondary, that is the initial response to vaccination is not maintained. At the time of TBEV infection that resulted in breakthrough TBE we had no information on the immunological status of our 39 patients and therefore can only surmise that their protective antibody levels were too low and the anamnestic response too slow to prevent the disease from developing [14] .
The proportion of patients with specific IgM antibody responses was lower in the subgroup with complete basic vaccination than in the subgroup with only two doses of vaccine (in the former group serum IgM antibodies were absent in nine of 25 [36%, 95% CI: 18.0-57.5%] patients, in the latter in three of 14 [21%, 95% CI 4.7-50.8%] patients), but there were no substantial differences regarding specific IgG antibody responses or IgG avidity. It is of interest that, despite the short duration of the illness (median 4 days from the beginning of the meningoencephalitic phase), intrathecal production of specific IgG antibodies was identified in all our patients with breakthrough disease, even in the two who presented with a serum antibody pattern indicative of primary vaccine failure.
Our study has several limitations. In addition to the previously mentioned lack of appropriate data that would enable assessment of vaccination field efficacy, and the limited number of patients with breakthrough TBE not allowing reliable appraisal of the outcome of the disease in this group, we also did not assess the presence of neutralizing antibodies. Although the concordance of diagnostic antibodies (as determined in ELISA) and protective (neutralizing) antibodies has been reported as high as 98% [16, 33, 34] , this remains a substantial limitation of the study.
Conclusion
The findings of the present study in patients with vaccination breakthrough TBE corroborate previous results, such as vaccination failure occurring predominantly in older people (possibly due to decreasing immunological responsiveness to vaccination) and the presence of a particular specific serum antibody pattern indicating anamnestic response in the large majority of previously vaccinated persons (low or absent specific IgM antibodies associated with very high IgG antibody levels with high avidity at the beginning of the meningoencephalitic phase). The study also found that the acute illness is more severe in patients with vaccination breakthrough TBE than in sex-and age-matched patients who develop TBE without previous vaccination.
